Tempus AI, Inc. (TEM) Strengthens Precision Medicine with New Tools, Partnerships, and Growth Milestones [Yahoo! Finance]
Tempus AI, Inc. - Class A (TEM)
Company Research
Source: Yahoo! Finance
its Immune Profile Score Test accurately predicts patient outcomes for immune checkpoint inhibitor therapy, compared with conventional biomarkers. Consequently, it continues to demonstrate superior predictive accuracy, with a hazard ratio of 0.45. Source: unsplash On January 21, Tempus AI introduced Paige Predict, an AI-powered digital pathology tool designed to analyze H&E whole slide images and predict 123 biomarkers across 16 cancer types, helping clinicians decide which confirmatory tests to run when tissue samples are limited. Built following Tempus's 2025 acquisition of Paige, the tool is based on a foundation model trained on data from more than 200,000 patients and validated across multiple datasets. Despite operating at a loss, Tempus reported a 61.7% gross margin and says Paige Predict supports its broader goal of advancing precision medicine by embedding actionable insights directly into clinical reports. Earlier on January 11, Tempus AI, Inc. announced a record Total
Show less
Read more
Impact Snapshot
Event Time:
TEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEM alerts
High impacting Tempus AI, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
TEM
News
- Tempus AI, Inc. (TEM): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Ambry’s Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New GenesBusiness Wire
- Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield [Yahoo! Finance]Yahoo! Finance
- Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and YieldBusiness Wire
- Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional BiomarkersBusiness Wire
TEM
Earnings
- 11/4/25 - Beat
TEM
Sec Filings
- 2/4/26 - Form 4
- 1/30/26 - Form 4
- 1/28/26 - Form 144
- TEM's page on the SEC website